Douglas T Dieterich

Summary

Country: USA

Publications

  1. ncbi Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients
    Douglas T Dieterich
    Gastroenterology and Hepatology, Cabrini Medical Center, New York University School of Medicine, New York, New York 10003, USA
    J Infect Dis 185:S128-37. 2002
  2. ncbi HBV plus HCV, HCV plus HIV, HBV plus HIV
    James S Park
    Division of Liver Diseases, Department of Medicine, Mount Sinai Medical Center, 5 East 98th Street, 11th Floor, New York, NY 10029, USA
    Curr Gastroenterol Rep 8:67-74. 2006
  3. ncbi Interferon alfa-2b [correction of alpha-2b]and ribavirin for patients with chronic hepatitis C and normal ALT
    Ira M Jacobson
    Department of Gastroenterology and Hepatology, Weill Medical School of Cornell University, 450 East 69th Street, New York, NY 10021, USA
    Am J Gastroenterol 99:1700-5. 2004
  4. ncbi Treatment of hepatitis C virus in HIV patients: a review
    Nickolas Kontorinis
    Department of Medicine, Mount Sinai Hospital, New York, NY 10029, USA
    AIDS 19:S166-73. 2005
  5. ncbi Sustained virologic response with short-course ribavirin and peginterferon treatment in 2 patients coinfected with HIV and HCV genotype 1
    Mitesh R Patel
    Department of Medicine, Mount Sinai School of Medicine, New York University, New York, USA
    AIDS Read 16:164, 168-9; discussion 168-9. 2006
  6. ncbi HIV/HCV coinfection in clinical practice
    Douglas T Dieterich
    Mount Sinai Hospital, Department of Medicine, New York, NY 10029, USA
    J Int Assoc Physicians AIDS Care (Chic Ill) 3:S4-14; quiz S16-7. 2004
  7. ncbi HIV and liver diseases: recent clinical advances
    Cem Cengiz
    Division of Liver Diseases, Mount Sinai School of Medicine, One Gustave Levy Place, New York, NY 10029, USA
    Clin Liver Dis 9:647-66, vii. 2005
  8. ncbi Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study
    Daniel S Fierer
    Division of Infectious Diseases, Department of Medicine, Mount Sinai School of Medicine, New York, New York 10029, USA
    J Infect Dis 198:683-6. 2008
  9. ncbi Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen
    Stephanie A Santos
    Department of Medicine, Division of Liver Diseases, Mount Sinai School of Medicine, New York, New York 10029, USA
    Eur J Gastroenterol Hepatol 18:1247-53. 2006
  10. ncbi Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study
    Abraham Reichenberg
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    AIDS 19:S174-8. 2005

Detail Information

Publications51

  1. ncbi Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients
    Douglas T Dieterich
    Gastroenterology and Hepatology, Cabrini Medical Center, New York University School of Medicine, New York, New York 10003, USA
    J Infect Dis 185:S128-37. 2002
    ..Ribavirin-associated hemolytic anemia is a potential problem in a patient population that is already susceptible to anemia but is manageable with recombinant human erythropoietin (epoetin alfa)...
  2. ncbi HBV plus HCV, HCV plus HIV, HBV plus HIV
    James S Park
    Division of Liver Diseases, Department of Medicine, Mount Sinai Medical Center, 5 East 98th Street, 11th Floor, New York, NY 10029, USA
    Curr Gastroenterol Rep 8:67-74. 2006
    ..The viral interactions between these viruses are complex, and their treatment may be challenging for clinicians...
  3. ncbi Interferon alfa-2b [correction of alpha-2b]and ribavirin for patients with chronic hepatitis C and normal ALT
    Ira M Jacobson
    Department of Gastroenterology and Hepatology, Weill Medical School of Cornell University, 450 East 69th Street, New York, NY 10021, USA
    Am J Gastroenterol 99:1700-5. 2004
    ..Patients with CHC should not be excluded from treatment on the basis of ALT alone. Combination therapy with pegylated interferon and ribavirin should be evaluated in these patients...
  4. ncbi Treatment of hepatitis C virus in HIV patients: a review
    Nickolas Kontorinis
    Department of Medicine, Mount Sinai Hospital, New York, NY 10029, USA
    AIDS 19:S166-73. 2005
    ..ART-associated hepatotoxicity has been demonstrated to occur more frequently in co-infected individuals and may be severe or fatal in some instances. Thus treatment of HCV has become a priority in HIV infected individuals...
  5. ncbi Sustained virologic response with short-course ribavirin and peginterferon treatment in 2 patients coinfected with HIV and HCV genotype 1
    Mitesh R Patel
    Department of Medicine, Mount Sinai School of Medicine, New York University, New York, USA
    AIDS Read 16:164, 168-9; discussion 168-9. 2006
    ..Reported here are 2 cases of HIV-HCV-coinfected genotype-1 patients who discontinued treatment early (after 3 and 8 weeks) because of adverse effects yet had a sustained virologic response with undetectable HCV viral loads at follow-up...
  6. ncbi HIV/HCV coinfection in clinical practice
    Douglas T Dieterich
    Mount Sinai Hospital, Department of Medicine, New York, NY 10029, USA
    J Int Assoc Physicians AIDS Care (Chic Ill) 3:S4-14; quiz S16-7. 2004
    ..The risk of HAART-related hepatotoxicity is greater in coinfected patients and therefore requires special consideration and close monitoring...
  7. ncbi HIV and liver diseases: recent clinical advances
    Cem Cengiz
    Division of Liver Diseases, Mount Sinai School of Medicine, One Gustave Levy Place, New York, NY 10029, USA
    Clin Liver Dis 9:647-66, vii. 2005
    ..This article reviews various liver manifestations in patients who have HIV and the recent advances in diagnostic and therapeutic options...
  8. ncbi Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study
    Daniel S Fierer
    Division of Infectious Diseases, Department of Medicine, Mount Sinai School of Medicine, New York, New York 10029, USA
    J Infect Dis 198:683-6. 2008
    ..No cause of liver damage other than acute HCV infection was identified. The specific pathways leading to periportal fibrosis in HIV-infected men with newly acquired HCV infection require investigation...
  9. ncbi Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen
    Stephanie A Santos
    Department of Medicine, Division of Liver Diseases, Mount Sinai School of Medicine, New York, New York 10029, USA
    Eur J Gastroenterol Hepatol 18:1247-53. 2006
    ..Tenofovir, in combination with emtricitabine, may be an alternative treatment for those with detectable hepatitis B viral DNA on adefovir...
  10. ncbi Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study
    Abraham Reichenberg
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    AIDS 19:S174-8. 2005
    ....
  11. ncbi Special considerations and treatment of patients with HBV-HIV coinfection
    Douglas T Dieterich
    Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA
    Antivir Ther 12:H43-51. 2007
    ..This review discusses the current status of treatment of hepatitis B in the setting of HIV infection. It describes emerging therapeutic strategies and addresses challenges in the treatment of coinfection...
  12. ncbi Acute pancreatitis associated with interferon and ribavirin therapy in patients with chronic hepatitis C
    Swati Chaudhari
    New York University School of Medicine. New York, New York, USA
    Dig Dis Sci 49:1000-6. 2004
    ..In these individuals, pancreatitis is often severe enough to warrant hospital admission, although symptoms resolve promptly after discontinuation of antiviral therapy...
  13. ncbi Hepatitis B therapies and antiviral resistance detection and management
    Giselle Holness
    Department of Medicine, Director of Outpatient Hepatology, Division of Liver Diseases, Mount Sinai School of Medicine, Annenberg 21 42, New York, NY 10029, USA
    Expert Rev Gastroenterol Hepatol 3:693-9. 2009
    ..It is important that clinicians monitor for therapeutic efficacy and resistance, so as to optimize the management of chronic HBV...
  14. ncbi Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa
    Douglas T Dieterich
    Mount Sinai School of Medicine, New York, New York 10029-6574, USA
    Am J Gastroenterol 98:2491-9. 2003
    ..Further research is warranted to determine the potential impact on outcomes, including quality of life and sustained viral response rate...
  15. ncbi Short communication: Inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users
    Kathryn E Childs
    Division of Infectious Diseases, Mount Sinai School of Medicine, New York, New York 10029, USA
    AIDS Res Hum Retroviruses 26:855-9. 2010
    ..Because TDF is a potent and widely used antiretroviral drug, information about cofactors that may exacerbate its side effects is of significant clinical value...
  16. ncbi Current status of the use of growth factors and other adjuvant medications in patients receiving peginterferon and ribavirin
    Nickolas Kontorinis
    Department of Medicine, Mount Sinai Hospital, New York, NY, USA
    Rev Gastroenterol Disord 4:S39-47. 2004
    ..However, emerging data suggest that utilization of hematopoietic growth factors can provide a useful adjunct to treatment and optimize sustained virologic response rates...
  17. ncbi Intrahepatic CD4+ cell depletion in hepatitis C virus/HIV-coinfected patients
    P Wilfredo Canchis
    Center for the Study of Hepatitis C, Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
    J Acquir Immune Defic Syndr 37:1125-31. 2004
    ..09 cell/HPF) and monoinfected patients (0.45 +/- 0.08 cell/HPF). In conclusion, HIV coinfection is associated with fewer portal CD4 cells and increased lobular lymphocyte apoptosis that may impact on the natural history of HCV infection...
  18. ncbi Disease management--constructing optimal NRTI-based combinations: past, present, and future
    Douglas T Dieterich
    Department of Medicine, The Mount Sinai Medical Center, New York, NY, USA
    MedGenMed 8:16. 2006
  19. ncbi Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors
    Douglas T Dieterich
    Department of Medicine, Mt Sinai Medical Center, New York, New York 10029, USA
    Clin Infect Dis 38:S80-9. 2004
    ..3% of nevirapine-treated patients) of these elevations were asymptomatic. Symptomatic hepatic events were seen in 4.9% (3.2%-8.9%) of nevirapine-treated patients...
  20. ncbi Toxicity of non-nucleoside analogue reverse transcriptase inhibitors
    Nickolas Kontorinis
    Department of Medicine, Mount Sinai School of Medicine, New York, New York 10029, USA
    Semin Liver Dis 23:173-82. 2003
    ..Close monitoring of transaminases is suggested in all patients commencing HAART, especially those with preexisting liver disease and coinfection with viral hepatitis...
  21. ncbi HIV and hepatitis B virus: options for managing coinfection
    Douglas T Dieterich
    Mt Sinai School of Medicine, New York, NY, USA
    Top HIV Med 11:16-9. 2003
    ..However, newer treatment options for chronic HBV infection increase the potential for successful management...
  22. ncbi The HIV/HCV-coinfected patient and new treatment options
    Marie Louise C Vachon
    Division of Infectious Diseases, Mount Sinai School of Medicine, New York, NY 10029, USA
    Clin Liver Dis 15:585-96. 2011
    ..This article reviews the latest predictive factors of response to HCV treatment with the current standard of care in HIV-coinfected patients, and new treatment options...
  23. ncbi Long-term complications of nucleoside reverse transcriptase inhibitor therapy
    Douglas T Dieterich
    Department of Medicine, Mount Sinai School of Medicine, New York University, New York, USA
    AIDS Read 13:176-84, 187. 2003
    ..Mechanisms by which NRTIs may produce these effects are discussed, as are differential effects of agents in this class and management options...
  24. ncbi Hematologic disorders associated with hepatitis C virus infection and their management
    Douglas T Dieterich
    Department of Medicine, Mount Sinai Medical Center, New York, New York, USA
    Clin Infect Dis 37:533-41. 2003
    ..This review highlights the pharmacology, risks, and benefits of recombinant hematopoietic growth factor therapy in HCV-infected patients...
  25. ncbi Hepatitis C infection in HIV. Interview by Vicki Glaser
    Douglas T Dieterich
    Department of Medicine, Mount Sinai School of Medicine, New York, New York, USA
    AIDS Patient Care STDS 18:127-30. 2004
  26. ncbi Mortality in hepatitis C virus-infected patients with a diagnosis of AIDS in the era of combination antiretroviral therapy
    Andrea D Branch
    Division of Liver Diseases, Mount Sinai School of Medicine, New York, New York 10029, USA
    Clin Infect Dis 55:137-44. 2012
    ....
  27. ncbi Human immunodeficiency virus and the liver: lessons learned and still to be learned
    Douglas T Dieterich
    Department of Gastroenterology, New York University School of Medicine, New York, New York 10001, USA
    Semin Liver Dis 23:107-14. 2003
  28. ncbi The development of hepatoportal sclerosis and portal hypertension due to didanosine use in HIV
    Thomas D Schiano
    Division of Liver Diseases, Department of Medicine, The Mount Sinai Medical Center, New York, NY, USA
    Virchows Arch 458:231-5. 2011
    ..This case demonstrates the development of HPS resulting from a drug-induced microvascular injury. The paired biopsies demonstrate that the initial vascular injury may disappear but that the portal hypertension and HPS progress...
  29. ncbi Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors
    Ron Palmon
    Department of Medicine, New York University School of Medicine, New York City, New York, USA
    J Acquir Immune Defic Syndr 29:340-5. 2002
    ..HBV or HCV was not associated with a significant increase in AST or ALT elevations. We conclude that NNRTIs are relatively free from hepatotoxicity in this population, despite the presence of coinfection with HBV or HCV...
  30. ncbi Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection
    Milos Opravil
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
    J Acquir Immune Defic Syndr 47:36-49. 2008
    ..The impact of baseline CD4 status on hepatitis C virus (HCV) treatment response among patients with HIV/HCV coinfection was investigated using data from a randomized study of peginterferon alfa-2a (40KD) + ribavirin (Peg-IFN/RBV)...
  31. ncbi Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection
    Gregory J Dore
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia
    AIDS 21:1555-9. 2007
    ..To identify baseline characteristics predictive of a sustained virological response (SVR) in patients with HIV-hepatitis C virus (HCV) co-infection treated with interferon-based therapy...
  32. ncbi Treatment of acute hepatitis C in an HIV-positive man with pegylated interferon and ribavirin for 24 weeks
    Nila Rafiq
    AIDS Read 17:561-4. 2007
    ..After 4 weeks of therapy, the patient's HCV RNA level became undetectable and remained undetectable 1 year after the 24-week treatment course...
  33. ncbi Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection
    John Hornberger
    The SPHERE Institute Acumen, LLC, Burlingame, CA 94010, USA
    J Clin Virol 36:283-91. 2006
    ..The cost-effectiveness of treating these patients with peginterferon alfa-2a/ribavirin has yet to be explored from a US societal perspective...
  34. ncbi Daily versus thrice-weekly interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected persons: a multicenter randomized controlled trial
    Mark S Sulkowski
    Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    J Acquir Immune Defic Syndr 35:464-72. 2004
    ..In conclusion, SVR was achieved in 19% of HIV/HCV coinfected subjects treated with daily IFN plus RBV, but the effectiveness of therapy was substantially diminished by relatively high rates of treatment-related toxicity...
  35. ncbi Editorial comment: liver disease in the HIV-infected patient--the courage to treat
    Douglas T Dieterich
    AIDS Read 13:500-1. 2003
  36. ncbi Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study
    Nezam H Afdhal
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Gastroenterology 126:1302-11. 2004
    ..This study assessed whether epoetin alfa could maintain RBV dose, improve quality of life (QOL), and increase hemoglobin (Hb) in anemic HCV-infected patients...
  37. ncbi Acute HIV seroconversion in a patient receiving pegylated interferon for treatment of hepatitis C
    Elana Maser
    University of Toronto, Toronto, Canada
    AIDS Read 13:279-80, 287. 2003
    ..However, the diagnosis of HIV infection during treatment of hepatitis C has not been reported. We present a case of acute HIV seroconversion in a patient who was not responding to interferon therapy for treatment of hepatitis C...
  38. ncbi Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy
    Paul J Pockros
    Scripps Clinic, La Jolla, CA 92037, USA
    Hepatology 40:1450-8. 2004
    ..Hb improvement was an independent predictor of HRQL improvement in these patients. In conclusion, epoetin alfa provided clinically significant HRQL improvement in HCV-infected patients receiving IFN/RBV therapy...
  39. ncbi Epoetin alfa once weekly improves anemia in HIV/hepatitis C virus-coinfected patients treated with interferon/ribavirin: a randomized controlled trial
    Mark S Sulkowski
    J Acquir Immune Defic Syndr 39:504-6. 2005
  40. ncbi The challenge of hepatitis C and HIV co-infection
    Damaris C Carriero
    Division of Liver Diseases, Mount Sinai School of Medicine, Manhattan, NY, USA
    Body Posit 18:8-12, 15-7. 2005
  41. ncbi Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients
    Francesca J Torriani
    Department of Medicine, Division of Infectious Diseases, University of California, San Diego, Antiviral Research Center, CA 92103, USA
    N Engl J Med 351:438-50. 2004
    ....
  42. ncbi Editorial comment: a tale of two viruses
    Douglas T Dieterich
    AIDS Read 12:448-9. 2002
  43. ncbi Hepatitis C management in HIV infection--where is the controversy?
    Douglas T Dieterich
    AIDS Read 12:22-3. 2002
  44. ncbi A treatment algorithm for the management of chronic hepatitis B virus infection in the United States
    Emmet B Keeffe
    Stanford University Medical Center, 750 Welch Road, Suite 210, Palo Alto, California 94304 1509, USA
    Clin Gastroenterol Hepatol 2:87-106. 2004
    ....
  45. ncbi Chronic hepatitis B: preventing, detecting, and managing viral resistance
    Emmet B Keeffe
    Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
    Clin Gastroenterol Hepatol 6:268-74. 2008
    ..Despite the substantial advances in treatment made to date, new agents with novel viral targets will be needed for patients who ultimately may fail second- or third-line therapy...
  46. ncbi Hepatic steatosis in HIV/HCV co-infected patients: correlates, efficacy and outcomes of anti-HCV therapy: a paired liver biopsy study
    Maribel Rodriguez-Torres
    Fundacion de Investigacion de Diego, Avenida De Diego 359, Santurce, PR 09909, USA
    J Hepatol 48:756-64. 2008
    ..A large population of patients from the AIDS Pegasys Ribavirin International Co-infection Trial (APRICOT) had paired liver biopsies interpreted and graded for steatosis along with lipid measurements and anthropometric data...
  47. ncbi Risk of immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis
    John H Kempen
    Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Ophthalmology 113:684-94. 2006
    ..To evaluate the prevalence of and risk factors for immune recovery uveitis (IRU) in eyes of patients with AIDS and cytomegalovirus (CMV) retinitis...
  48. ncbi Editorial comment: HIV and HBV coinfection--a coming-of-age in treatment strategies
    Aftab Ala
    AIDS Read 14:134-5. 2004
  49. ncbi Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study
    Norbert Brau
    Bronx Veterans Affairs VA Medical Center, Infectious Disease Section 111F, 130 West Kingsbridge Road, Bronx, NY 10468, USA
    J Hepatol 47:527-37. 2007
    ..HIV-infected patients now live longer and often have complications of liver disease, especially with hepatitis B or C virus coinfection. Limited data are available on those with hepatocellular carcinoma (HCC)...
  50. ncbi A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update
    Emmet B Keeffe
    Division of Gastroenterology and Hepatology, Stanford University Medical Center, CA 94304, USA
    Clin Gastroenterol Hepatol 4:936-62. 2006
    ..Issues for consideration include efficacy, safety, incidence of resistance, method of administration, and cost...
  51. ncbi Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B
    Emmet B Keeffe
    Stanford University School of Medicine, Stanford, California 94304 1509, USA
    Clin Gastroenterol Hepatol 5:890-7. 2007
    ..Future studies of the use of the roadmap concept in improving outcomes of chronic hepatitis B are warranted...